Cargando…

Etranacogene dezaparvovec for hemophilia B gene therapy

The treatment landscape for hemophilia has been rapidly changing with introduction of novel therapies. Gene therapy for hemophilia is a promising therapeutic option for sustained endogenous factor production to mitigate the need for prophylactic treatment to prevent spontaneous and traumatic bleedin...

Descripción completa

Detalles Bibliográficos
Autor principal:	Thornburg, Courtney D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032433/ https://www.ncbi.nlm.nih.gov/pubmed/37181105 http://dx.doi.org/10.1177/26330040211058896

Ejemplares similares

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy
por: von Drygalski, Annette, et al.
Publicado: (2022)

Treatment adherence in hemophilia
por: Thornburg, Courtney D, et al.
Publicado: (2017)

Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia
por: Thornburg, Courtney D., et al.
Publicado: (2023)

Gene Therapy for Hemophilia A: A Mixed Methods Study of Patient Preferences and Shared Decision-Making
por: Limjoco, Jacqueline, et al.
Publicado: (2023)

The odds and implications of coinheritance of hemophilia A and B
por: Karch, Corinne, et al.
Publicado: (2020)

Gene Therapy Approaches for the Treatment of Hemophilia B
por: Soroka, Anastasiia B., et al.
Publicado: (2023)

Developments in the treatment of hemophilia B: focus on emerging gene therapy
por: Cancio, Maria I, et al.
Publicado: (2013)

Gene Therapy in Hemophilia: Recent Advances
por: Rodríguez-Merchán, E. Carlos, et al.
Publicado: (2021)

Gene therapy in PIDs, hemoglobin, ocular, neurodegenerative, and hemophilia B disorders
por: Odiba, Arome Solomon, et al.
Publicado: (2021)

The Arrival of Gene Therapy for Patients with Hemophilia A
por: Castaman, Giancarlo, et al.
Publicado: (2022)

Big stride in gene therapy for hemophilia B in China
por: Wang, Jianmin, et al.
Publicado: (2023)

The intersection of vector biology, gene therapy, and hemophilia
por: Lisowski, Leszek, et al.
Publicado: (2021)

Emerging and future therapies for hemophilia
por: Carr, Marcus E, et al.
Publicado: (2015)

Hemophilia Gene Therapy: Approaching the First Licensed Product
por: Batty, Paul, et al.
Publicado: (2021)

Adenoviral Vectors for Hemophilia Gene Therapy
por: Brunetti-Pierri, N, et al.
Publicado: (2013)

Platelet-Targeted Gene Therapy for Hemophilia
por: Shi, Qizhen
Publicado: (2018)

Recent Advances in Hemophilia Gene Therapy
por: Karimipoor, Morteza
Publicado: (2019)

Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century
por: Arruda, Valder R., et al.
Publicado: (2020)

Gene Therapy and Hemophilia: Where Do We Go from Here?
por: Bolous, Nancy S, et al.
Publicado: (2022)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

The Molecular Basis of FIX Deficiency in Hemophilia B
por: Shen, Guomin, et al.
Publicado: (2022)

The Need for Gene Therapy for the Effective Treatment of Hemophilia
por: Wynn, Tung, et al.
Publicado: (2012)

Gene Therapy in Hemophilia: From Hype to Hope
por: Schutgens, Roger
Publicado: (2018)

Advanced therapies for the treatment of hemophilia: future perspectives
por: Liras, Antonio, et al.
Publicado: (2012)

Emerging therapies for hemophilia: controversies and unanswered questions
por: Arruda, Valder R., et al.
Publicado: (2018)

Immunogenicity of Current and New Therapies for Hemophilia A
por: Prezotti, Alessandra N. L., et al.
Publicado: (2022)

Hemophilia therapy: the future has begun
por: Mannucci, Pier Mannuccio
Publicado: (2020)

A Case of Acquired Hemophilia A and Congenital Hemophilia B
por: Fortier, Julia C, et al.
Publicado: (2022)

Manual therapy in the treatment of patients with hemophilia B and inhibitor
por: Cuesta-Barriuso, Rubén, et al.
Publicado: (2018)

Nonfactor Therapies for Hemophilia
por: Young, Guy
Publicado: (2023)

Hemophilia B: molecular pathogenesis and mutation analysis
por: Goodeve, A. C.
Publicado: (2015)

The Clinical Genetics of Hemophilia B (Factor IX Deficiency)
por: Miller, Connie H
Publicado: (2021)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

New developments in the management of moderate-to-severe hemophilia B
por: Nazeef, Moniba, et al.
Publicado: (2016)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021)

Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
por: Miao, Carol H.
Publicado: (2016)

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B
por: Nayak, Sushrusha, et al.
Publicado: (2011)

Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis
por: Croteau, Stacy E, et al.
Publicado: (2021)

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2018)

Gene Therapy for Hemophilia A: How Long Will It Last?
por: Schutgens, Roger E. G.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fdksv3cadv71jrtbimvrqtkkbd